Mr. Andre Larente reports

DIAGNOS PROVIDES MARKET ACTIVITY UPDATE

At the request of IIROC, Diagnos Inc. has confirmed that the corporation's management is unaware of any material change in the corporation's operations that would account for the recent increase in market activity.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence tool, CARA (computer-assisted retina analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's artificial intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is: accessible securely over the Internet; compatible with all recognized image formats and brands of fundus cameras; and EMR (electronic medical record) compatible. CARA is a cost-effective tool for screening large numbers of patients in real time. CARA complies with local regulations; is U.S. Food and Drug Administration cleared for commercialization in the United States; is Health Canada licensed for commercialization in Canada; is licensed by the Saudi Food and Drug Authority; is licensed by COFEPRIS in Mexico; and is CE marking compliant in Europe.

We seek Safe Harbor.